Acknowledgements We would like to acknowledge the contribution of Naveen Lancy Saldanha of Norhas Histology research lab for his assistance in preparing the histology slides
Dehydration symptoms typically worsen throughout the day if fluids arent replenished, whilst medication side effects often follow a pattern related to injection timing
Enforcement has been consistent throughout 2025 and 2026
Walker, MD Saint Francis Medical Center NASS Patient Safety Committee Member Cape Girardeau, MO Introduction and Mechanism of Action Glucagon-like peptide-1 (GLP-1) agonists are recognized for their efficacy in managing diabetes mellitus and aiding weight loss.1 They also reduce cardiovascular risk.2,3,4 The mechanism of action involves mimicking GLP-1, an incretin hormone that enhances insulin secretion after an oral glucose load.5,6 Beyond these effects, GLP-1 agonists are involved in inhibiting glucagon secretion, thus stabilizing blood glucose levels
Patientcentered considerations Eligibility and benefit must be weighed against individual comorbidities, preferences, and treatment burden
By end user, the specialty clinics and gastroenterology centers segment is expected to grow at a notable CAGR over the projected period
